Clinical Research Coordinator

IQVIA Clinical Decision Support Tool wins 2026 AI Breakthrough Award for Predictive Modeling Solution of the Year. Published: 22/08/2026 | Last Updated: 23/08/2026 IQVIA Clinical Decision Support Tool has been named winner of the 2026 AI Breakthrough Award for Predictive Modeling Solution of the Year, IQVIA (NYSE:IQV) announced on August 20, 2026. The AI-enabled tool, developed by IQVIA in collaboration with Breakthrough T1D, was recognized for addressing a persistent and costly problem in diabetes care: adults with type 1 diabetes who are misclassified as having type 2 diabetes. IQVIA is a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries. The company disclosed the award from Research Triangle Park, North Carolina, describing the recognition as validation of its expanding portfolio of artificial intelligence solutions built for clinical and commercial healthcare use cases. Misclassification between type 1 diabetes (T1D) and type 2 diabetes (T2D) is not a minor coding error. Because the two conditions require different treatment pathways, an incorrect diagnosis can delay the introduction of insulin therapy that T1D patients need, raising the risk of severe and sometimes life-threatening complications such as diabetic ketoacidosis. The IQVIA Clinical Decision Support Tool was built specifically to catch these misclassifications earlier in the care pathway, using predictive modeling to flag patient records that warrant a second look. The tool is powered by IQVIA Healthcare-grade AI(R), a proprietary framework the company says is designed to meet the accuracy, privacy and regulatory standards required for use in real clinical settings rather than experimental pilots. That distinction matters for health systems evaluating whether an AI-enabled tool is ready for production use across large patient populations. IQVIA Clinical Decision Support Tool targets type 1 diabetes misdiagnosis. The scale of the misdiagnosis problem is part of what makes the IQVIA Clinical Decision Support Tool notable. Health systems attempting to identify misclassified T1D patients manually would typically need to review tens of thousands of patient charts to find a small number of true positives, a workload that is rarely practical given constrained clinical staffing and competing priorities. By applying predictive modeling to existing patient data, the IQVIA Clinical Decision Support Tool narrows that universe dramatically before a clinician ever opens a chart. Rather than asking care teams to sift through an entire population, the tool surfaces a short, prioritized list of patients whose records show patterns consistent with a T1D profile despite a T2D diagnosis on file. JobFinder Listing That triage function is the core of why the AI Breakthrough Awards program selected the tool for its Predictive Modeling Solution of the Year category. The program recognizes innovation and performance across the global AI market, and predictive modeling applied to a well-defined clinical gap, rather than a broad or speculative use case, is precisely the kind of measurable outcome the award category is built to highlight. IQVIA Clinical Decision Support Tool delivers measurable screening gains. According to IQVIA, the results reported from deployment of the tool are substantial. The IQVIA Clinical Decision Support Tool cut the overall screening workload by 99.5%, narrowing what would have been a review of roughly 60,000 patient charts down to approximately 300, or about 200 times fewer chart reviews for care teams to complete. Diagnostic yield improved just as sharply. Among patients flagged by the tool, 28% were confirmed or suspected to have type 1 diabetes, compared with a 0.22% baseline rate of T1D confirmation in the broader unscreened population. IQVIA characterizes that shift as an approximately 127-fold increase in diagnostic yield, meaning clinical staff spend their limited chart-review time on patients who are dramatically more likely to actually have the condition the tool is designed to catch. IQVIA said the combined effect of the reduced workload and higher yield is a faster path to correct diagnosis and appropriate treatment for affected patients, which the company links to a lower risk of downstream complications and improved long-term outcomes for people living with undiagnosed or misdiagnosed T1D. Breakthrough T1D partnership shapes IQVIA Clinical Decision Support Tool rollout. The IQVIA Clinical Decision Support Tool was configured in direct partnership with Breakthrough T1D, described in the announcement as the leading global type 1 diabetes research and advocacy nonprofit organization. That collaboration shaped how the tool was built to address specific, persistent gaps in T1D care beyond diagnosis alone, including delayed identification, missed ongoing monitoring, and under-treatment once a correct diagnosis is made. Pairing a disease-specific advocacy organization with a health-data and analytics company is a deliberate design choice. Breakthrough T1D contributes clinical and patient-community context about how T1D actually presents and is missed in practice, while IQVIA contributes the data infrastructure, modeling capability and Healthcare-grade AI(R) framework needed to operationalize that knowledge at population scale across health system records. IQVIA Clinical Decision Support Tool adds to healthcare-grade AI portfolio. The 2026 AI Breakthrough Award adds to what IQVIA describes as a growing portfolio of award-winning AI solutions. IQVIA framed the recognition as reinforcement of its broader strategy of applying Healthcare-grade AI(R) to solve clinical challenges that have resisted simpler technology fixes, positioning predictive, clinically embedded tools like this one as a template for future product development. IQVIA's portfolio of solutions is powered by IQVIA Connected Intelligence(TM), which the company says combines high-quality health data, Healthcare-grade AI(R), advanced analytics and deep domain expertise into actionable insights for biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders. With approximately 94,000 employees operating in over 100 countries, IQVIA positions itself as a company built to deploy tools like the Clinical Decision Support Tool at the scale global health systems require, while maintaining what it describes as best-in-class approaches to patient privacy, regulatory compliance and patient safety throughout the AI development lifecycle. IQVIA, led by chief executive officer Ari Bousbib and headquartered in Durham, North Carolina, reported revenues of $16.3 billion for 2025. The company's decision to highlight the IQVIA Clinical Decision Support Tool win alongside its other 2026 disclosures reflects a broader pattern: IQVIA has used recent announcements, including an Everest Group ranking as the top-scored pharmaceutical technology provider for 2026 and a strategic collaboration with Medera on cardiac gene therapy research, to underscore how its data and AI capabilities extend across clinical development, commercial insight and now direct point-of-care decision support.

Healthcare data technology market: Challenges in privacy and compliance. Healthcare organizations are sitting on more data than ever before - electronic health records, connected devices, claims, imaging, and real-world evidence - and the race is on to turn that raw information into something usable. That race is fueling rapid growth in the healthcare data technology market, a space built around integrating, standardizing, securing, and monetizing health data at scale. Here's a closer look at where the market stands today, what's driving it forward, and the roadblocks still standing in the way. Key Market Facts The global healthcare data technology market was valued at USD 3.1 billion in 2024 and is projected to grow from USD 4.0 billion in 2026 to USD 9.5 billion by 2033, expanding at a compound annual growth rate of 13.4% between 2025 and 2033. A few other numbers worth noting: * North America led the market in 2024, capturing a 46.5% revenue share, while Asia Pacific is on track to be the fastest-growing region going forward. * By technology, the health data integration and monetization segment dominated in 2024, holding more than 66.55% of total revenue, as providers work to unify EHRs, clinical trial data, and real-world evidence into single, usable pipelines. * The data harmonization and structuring segment, though smaller today, is expected to post the fastest growth rate of any segment over the forecast period, largely thanks to AI and NLP tools that can standardize messy, unstructured clinical data. * EHR adoption remains the backbone of this demand: as of December 2024, roughly 88% of U.S. office-based physicians were using an EMR/EHR system, with nearly 78% on a certified platform - a base that keeps generating more data to integrate and analyze. * The competitive landscape is notably fragmented, with dozens of established and emerging vendors - including IQVIA, Veeva Systems, Oracle (Cerner), Optum, Datavant, TriNetX, and Flatiron Health - all competing for share, which keeps innovation and partnership activity high. Major Industry Trends AI and advanced analytics are moving from pilot to production. Vendors are embedding generative AI and machine learning directly into data platforms rather than treating them as add-ons. Oracle's newly launched AI Data Platform, for example, is designed to help enterprises build AI-ready data lakes and deploy AI-driven applications directly on top of unified data. Global harmonization initiatives are reshaping the data landscape. Governments and health systems are investing heavily in standardizing and connecting fragmented health records. Europe's Health Data Space regulation, formally adopted in 2025, sets a legally binding framework for cross-border health data access across the EU, covering both direct patient care and secondary research use. The UK has committed roughly £600 million toward a national Health Data Research Service, while Germany has launched a similarly ambitious medical informatics funding program - all aimed at making health data more accessible for research and care. Discover more Internet & Telecom Commercial Distribution Public Relations Interoperability is becoming a regulatory mandate, not just a best practice. In the U.S., federal regulators have intensified enforcement of information-blocking rules under the 21st Century Cures Act, pushing providers and vendors to make electronic health information more freely accessible and exchangeable. Strategic partnerships and M&A are accelerating capability-building. Rather than building every capability in-house, companies are teaming up or acquiring their way into new strengths - from IQVIA and Veeva's long-term global partnership to streamline clinical trials, to Samsung's acquisition of digital health platform Xealth, to Commvault's move to acquire data security firm Satori Cyber to strengthen protections around AI training data. Social determinants of health (SDOH) and real-world data are being folded into core platforms. Partnerships like HealthEdge and Unite Us embedding SDOH data into care management platforms reflect a broader shift toward more holistic, value-based data models that go beyond clinical records alone. Emerging technologies are tackling harmonization at scale. Graph databases, federated learning frameworks, and AI-driven semantic mapping are increasingly used to link genomic, clinical, and multi-institutional datasets - enabling collaborative research without centralizing sensitive patient data. Need data specific to your market or segment? This report can be tailored with additional countries, segments, or data points to match your exact research needs - with free customization available on purchase. Request Report Customization Primary System Challenges Data fragmentation across legacy systems. Many healthcare organizations still operate with claims, patient records, and lab results scattered across disconnected legacy systems, creating operational bottlenecks and slowing down everything from claims processing to clinical research. Regulatory complexity and compliance costs. Stringent privacy and security frameworks - HIPAA, GDPR, and a growing patchwork of regional health data governance rules - demand robust compliance and audit capabilities. While these regulations push innovation in secure data management, they also add real implementation complexity and cost for both providers and vendors. Discover more Communications & Media Studies communication Interoperability gaps between platforms. Despite widespread EHR adoption, getting different systems to talk to each other in a standardized way (HL7/FHIR and beyond) remains a persistent hurdle, particularly for organizations trying to merge imaging, genomic, and unstructured clinical data. Balancing data monetization with privacy. As organizations look to unlock value from health data - through analytics, research partnerships, or licensing - they must simultaneously protect patient privacy, driving demand for de-identification, pseudonymization, and governance tools that can slow down time-to-insight. Scalability under growing data volumes. As data volume and variety expand (from wearables, genomics, and real-world evidence), organizations need cloud-native, auto-scaling infrastructure - a shift that isn't trivial for institutions still running on manual or semi-automated processes. Regional disparities in infrastructure and investment. While North America and Europe are pushing ahead with major national data initiatives, regions like Latin America and parts of MEA are still working to modernize foundational health data infrastructure, creating uneven adoption rates globally. The bigger picture: healthcare data technology is no longer a back-office IT concern - it's becoming central to how care gets delivered, how research gets funded, and how health systems compete. Organizations that solve for interoperability, compliance, and scalability today will be the ones best positioned to capture value as the market roughly triples in size by 2033. Discover more communications Business & Industrial Want the Full Picture? See who's leading the market. Get access to detailed profiles of the key players shaping the healthcare data technology space - including IQVIA, Veeva Systems, Oracle, Optum, Datavant, and more - along with their strategies, partnerships, and market positioning. Explore Key Players Explore our dedicated business services: * U.S. Healthcare Facility Mapping & Intelligence Portal - Claims analytics (MS-DRG, service lines, ICD-10 outpatient, APC reimbursement, CPT-level) plus hospital-level financials (balance sheet, income statement, uncompensated care, financial health dashboards), covering 25,000+ healthcare facilities - including 7,000+ hospitals, independent pharmacies, freestanding EDs, concierge physicians, and ASCs. * Brainshare Consulting - End-to-end business consulting services including Opportunity assessment, GTM support, Competitive intelligence, and Consumer Analytics. * Custom Research - Get a market intelligence report tailored to your specific requirements and aligned with your business goals. * Consumer Insights - Capture real, evolving consumer sentiment and behavior to help you make data driven strategies. * Horizon Databooks - Access the world's largest portal of Market Reports & Statistics * Investment Insights - Make investment decisions with data driven insights, powered by domain and technology * Signal (Pricing Intelligence) - Commodity price intelligence to drives strategic advantage. About us: Grand View Research, a market research and consulting company, provides syndicated research reports, customized research reports, and consulting services. Grand View Research database is used by the world's renowned academic institutions and Fortune 500 companies to understand the global and regional business environment. Our database features thousands of statistics and in-depth analysis on 46 industries in 25 major countries worldwide. Matched content.

IQVIA's ai-enabled Clinical Decision Support Tool wins 2026 AI Breakthrough Award for Predictive Modeling Solution of the Year. RESEARCH TRIANGLE PARK, N.C.-(BUSINESS WIRE)-IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, today announced that its AI-enabled Clinical Decision Support Tool, developed in collaboration with Breakthrough T1D, has won the 2026 AI Breakthrough Award for Predictive Modeling Solution of the Year. Powered by IQVIA Healthcare-grade AI(R), the tool tackles a long-standing problem in diabetes care: adults with type 1 diabetes (T1D) are often misclassified as having type 2 diabetes (T2D). That mistake delays the right treatment and raises the risk of serious, sometimes life-threatening complications. Results in practice: * Cut the screening workload by 99.5%, narrowing reviews from about 60,000 patients down to 300, or roughly 200 times fewer chart reviews. * Delivered a ~127x increase in diagnostic yield - 28% of flagged patients were confirmed or suspected to have T1D, versus a 0.22% baseline. * Accelerated the path to the right diagnosis and treatment, helping reduce the risk of complications and improving long-term outcomes. The Clinical Decision Support Tool was configured in partnership with Breakthrough T1D, the leading global T1D research and advocacy non-profit organization, to enable healthcare providers to close persistent gaps in care, such as delayed diagnosis, missed monitoring and under-treatment. The AI Breakthrough Awards recognize innovation and performance across the global AI market. This recognition reinforces IQVIA's leadership in applying Healthcare-grade AI(R) to solve complex clinical challenges and adds to IQVIA's growing portfolio of award-winning AI solutions helping to advance human health. About IQVIA IQVIA (NYSE:IQV) is a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries. IQVIA's portfolio of solutions are powered by IQVIA Connected Intelligence(TM) to deliver actionable insights and services built on high-quality health data, Healthcare-grade AI(R), advanced analytics, the latest technologies and extensive domain expertise. IQVIA is committed to using AI responsibly, with AI-powered capabilities built on best-in-class approaches to privacy, regulatory compliance and patient safety, and delivering AI to the high standards of trust, scalability and precision demanded by the industry. With approximately 94,000 employees in over 100 countries, including experts in healthcare, life sciences, data science, technology and operational excellence, IQVIA is dedicated to accelerating the development and commercialization of innovative medical treatments to help improve patient outcomes and population health worldwide. IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes. IQVIA's insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors and scientific advances, in an effort to advance their path toward cures. To learn more, visit www.iqvia.com. Kerri Joseph, IQVIA Investor Relations ([email protected]) +1.973.541.3558 August 21st, 2026 August 20th, 2026